Zynex Inc. (ZYXI)
| Bid | 1.46 |
| Market Cap | 44.54M |
| Revenue (ttm) | 144.81M |
| Net Income (ttm) | -28.66M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -1.58 |
| Forward PE | -3.4 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.5 |
| Volume | 109,411 |
| Avg. Volume (20D) | 286,174 |
| Open | 1.51 |
| Previous Close | 1.50 |
| Day's Range | 1.46 - 1.54 |
| 52-Week Range | 1.23 - 9.42 |
| Beta | 1.02 |
| Ex-Dividend Date | n/a |
About ZYXI
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ZYXI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
1 month ago · fool.com
Zynex Q2 Revenue Drops 55%Zynex Q2 Revenue Drops 55%
1 month ago · proactiveinvestors.com
Zynex eyes growth revival under new CEO, advances oximeter technologyZynex Inc (NASDAQ:ZYXI), a developer of non-invasive medical devices, is laying the foundation for a return to growth following a pivotal second quarter marked by leadership changes, operational strea...
2 months ago · proactiveinvestors.com
Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMIZynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard talked with Proactive about his decision to step down from his position after nearly three decades leading the medical device company. He described the cha...
3 months ago · proactiveinvestors.com
Zynex awarded UK patent for non-invasive sepsis monitoring technologyZynex Inc (NASDAQ:ZYXI) announced that it has been issued a UK patent for its multiparameter, non-invasive sepsis monitor. The company highlighted that its patented technology is designed to continuou...